ASCO has been awarded $11M of PCORI research funding to study CDK4/6 inhibitors dosing in older adults w metastatic breast cancer

In a post by ASCO on Twitter, it says, “We’re pleased to announce ASCO has been awarded $11M of The Patient-Centered Outcomes Research Institute funding to study CDK4/6 inhibitors dosing in older adults w metastatic breast cancer. Led by our CMO Julie Gralow, the aim is to improve outcomes & fill a real-world evidence gap.”

For details: Click here

Source: ASCO/Twitter